CN Patent

CN105853356B — Jak抑制剂的局部用制剂

Assigned to Because Of C1-Esteraseremmer-N Parent Corp · Expires 2019-07-16 · 7y expired

What this patent protects

本发明涉及包含(R)‑3‑环戊基‑3‑[4‑(7H‑吡咯并[2,3‑d]嘧啶‑4‑基)‑1H‑吡唑‑1‑基]丙腈或其药学上可接受的盐的用于局部皮肤施用的药物制剂，以及在治疗皮肤病症中的用途。

USPTO Abstract

本发明涉及包含(R)‑3‑环戊基‑3‑[4‑(7H‑吡咯并[2,3‑d]嘧啶‑4‑基)‑1H‑吡唑‑1‑基]丙腈或其药学上可接受的盐的用于局部皮肤施用的药物制剂，以及在治疗皮肤病症中的用途。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN105853356B
Jurisdiction: CN
Classification: —
Expires: 2019-07-16
Drug substance claim: No
Drug product claim: No
Assignee: Because Of C1-Esteraseremmer-N Parent Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.